News

Recent research highlights the potential of non-psychoactive cannabinoids—CBD, CBG, and CBN—as promising therapeutic tools for Autism Spectrum Disorder (ASD). CBD has shown efficacy in reducing anxiety, aggression, and sleep disturbances, while CBG may support cognitive function and reduce neuroinflammation. CBN, often associated with sleep improvement, is also being studied for its neurogenic properties. The most significant benefits appear when these compounds work together in full-spectrum formulations, leveraging the entourage effect to enhance symptom relief. While further large-scale studies are needed, these findings suggest that cannabinoids could play a transformative role in ASD treatment.
